International Stem Cell CORP (ISCO) stock
ISCOOTCPharmaceutical PreparationsFiscal year ends December 31
$0.28+0.00 (+0.89%)
Close on Oct 19, 2026Market cap $2.27MP/E –Yield –
International Stem Cell ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
International Stem Cell's ebitda for the twelve months ending Jun 30, 2026 was -$272.00K, down 310.9% year over year. For fiscal 2025 it was -$48.00K, down 134.8% from the year before. The highest annual figure on record is $138.00K in fiscal 2024.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$48.00K | -134.8% |
| FY2024 | Dec 31, 2024 | $138.00K | – |
| FY2023 | Dec 31, 2023 | -$469.00K | -1440.0% |
| FY2022 | Dec 31, 2022 | $35.00K | – |
| FY2021 | Dec 31, 2021 | -$1.66M | – |
| FY2020 | Dec 31, 2020 | -$2.57M | – |
| FY2019 | Dec 31, 2019 | -$5.44M | – |
| FY2018 | Dec 31, 2018 | -$3.17M | – |
| FY2017 | Dec 31, 2017 | -$4.62M | – |
| FY2016 | Dec 31, 2016 | -$4.52M | – |
| FY2015 | Dec 31, 2015 | -$4.09M | – |
| FY2014 | Dec 31, 2014 | -$8.22M | – |
| FY2013 | Dec 31, 2013 | -$7.08M | – |
| FY2012 | Dec 31, 2012 | -$9.34M | – |
| FY2011 | Dec 31, 2011 | -$10.86M | – |
| FY2010 | Dec 31, 2010 | -$10.17M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$7.00K | -103.2% |
| Q1 FY2026 | Mar 31, 2026 | -$156.00K | – |
| Q4 FY2025 | Dec 31, 2025 | -$259.00K | -346.7% |
| Q3 FY2025 | Sep 30, 2025 | $150.00K | – |
| Q2 FY2025 | Jun 30, 2025 | $221.00K | +11.1% |
| Q1 FY2025 | Mar 31, 2025 | -$160.00K | – |
| Q4 FY2024 | Dec 31, 2024 | $105.00K | – |
| Q3 FY2024 | Sep 30, 2024 | -$37.00K | – |
| Q2 FY2024 | Jun 30, 2024 | $199.00K | – |
| Q1 FY2024 | Mar 31, 2024 | -$129.00K | -343.4% |
| Q4 FY2023 | Dec 31, 2023 | -$376.00K | -432.7% |
| Q3 FY2023 | Sep 30, 2023 | -$70.00K | – |
| Q2 FY2023 | Jun 30, 2023 | -$117.00K | -277.3% |
| Q1 FY2023 | Mar 31, 2023 | $53.00K | -34.6% |
| Q4 FY2022 | Dec 31, 2022 | $113.00K | – |
| Q3 FY2022 | Sep 30, 2022 | -$266.00K | – |
| Q2 FY2022 | Jun 30, 2022 | $66.00K | – |
| Q1 FY2022 | Mar 31, 2022 | $81.00K | – |
| Q2 FY2021 | Jun 30, 2021 | -$365.00K | – |
| Q1 FY2021 | Mar 31, 2021 | -$501.00K | – |
| Q4 FY2020 | Dec 31, 2020 | -$672.00K | – |
| Q3 FY2020 | Sep 30, 2020 | -$756.00K | – |
| Q2 FY2020 | Jun 30, 2020 | -$789.00K | – |
| Q1 FY2020 | Mar 31, 2020 | -$392.00K | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.40M | – |
| Q3 FY2019 | Sep 30, 2019 | -$773.00K | – |
| Q2 FY2019 | Jun 30, 2019 | -$904.00K | – |
| Q1 FY2019 | Mar 31, 2019 | -$1.42M | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.17M | – |
| Q3 FY2018 | Sep 30, 2018 | -$588.00K | – |
| Q2 FY2018 | Jun 30, 2018 | -$323.00K | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.12M | – |
| Q4 FY2017 | Dec 31, 2017 | -$1.85M | – |
| Q3 FY2017 | Sep 30, 2017 | -$887.00K | – |
| Q2 FY2017 | Jun 30, 2017 | -$919.00K | – |
| Q1 FY2017 | Mar 31, 2017 | -$964.00K | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.09M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.18M | – |
| Q2 FY2016 | Jun 30, 2016 | -$1.17M | – |
See a number that looks wrong?